GSK Terminates $2.2B Neurodegenerative Drug Collaboration with Alector After Dual Phase Failures

Jul 09, 2026 16:24 CST Updated 16:24

GSK

Pharmaceutical R&D Manufacturer

Alector

Neurodegenerative Disease Therapeutics Developer

July 9,According to foreign media outlet Reuters, Alector stated, its partnersGSK has officially terminated the parties' agreement regardingTwo Neuroscience Antibody DrugsCooperation Agreement (latozinemab and nivisnebart). The cooperation shall expire on January 2, 2027.

GSK’s collaboration with Alector began in 2021, when the two parties reachedGlobal strategic collaboration aimed at developing and commercializing two clinical-stagePotential First-in-Class (FIC) Monoclonal Antibodies AL001 and AL101, with a maximum total amount of up to$2.2 billion($700 million upfront payment + $1.5 billion in milestone payments and sales royalties).

Unexpectedly, within a few years, both core candidate drugs sequentially encountered clinical failures, and the collaboration between the two parties gradually came to an end.

Among them, a collaborative drug, latozinemab（AL001）Targeting Sortilin (SORT1) to Treat Neurodegenerative Diseases Such as Frontotemporal Dementia by Regulating Progranulin LevelsIn 2025, the drug was developed for patients with frontotemporal dementia associated with GRN gene mutations.Phase III INFRONT-3 Study Fails to Meet Primary Endpoint, failing to significantly delay disease progression, dealt the first blow to the partnership between the two parties.

AnotherNew AD Drugsnivisnebartis aAnti-SIGLEC-3 (CD33) monoclonal antibody, designed to improve the progression of Alzheimer's disease by modulating microglial function. In April 2026,Alector Officially Announces Termination of Phase 2 PROGRESS-AD Clinical Trial Conducted in Collaboration with GSK—Following Completion of Interim Futility Analysis by the Independent Data Monitoring Committee,The study is no longer able to achieve the primary clinical endpoint of delaying the progression of early Alzheimer's disease.，GSK ultimately discontinued the development of this project.

Setbacks in Two Core Programs Plunge Alector into Crisis: Stock Plummets, Workforce Halved, and Strategy Overhauled to Preserve Cash; GSK’s Exit Returns Global Rights to Two Antibodies, Yet Their Development Prospects Remain Uncertain

Drug development for neurodegenerative diseases faces significant challenges, with high failure rates in pharmaceutical R&D for conditions such as Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease.Recently, Merck & Co. terminated its small-molecule candidate drug for Alzheimer’s diseaseMK-1167Phase II clinical trial,As disclosed, the failure to meet predefined efficacy endpoints was the primary issue, further underscoring the substantial challenges and long road ahead in R&D within this field.

End

Statement:The articles published on this official WeChat account (including original and reposted content) are intended for informational purposes only, with sources and authors duly credited. You are welcome to share them on your WeChat Moments or in large group chats.No unauthorized reproduction by media or institutions in any form to other platforms is permitted.。

Previous Reviews

1. ASCO 2026 | Chinese Innovative Drugs Enter the “Spotlight Moment”

2. Founder Reduces Holdings by Another 121 Million! Why Did Innovent Biologics Plunge?

3. Hengrui Unveils a “New Chapter”!